The type 2 5Ј-deiodinase (D2) appears to play an important role in maintaining the intracerebral T 3 content relatively constant during changes in thyroidal state. Previous studies have demonstrated that the regulation of this enzyme by thyroid hormone and its analogs occurs at a posttranslational level. The availability of the rat D2 complementary DNA now allows an assessment of whether pretranslational regulation of this enzyme also occurs in the cerebral cortex. In rats rendered hypothyroid by the addition of methimazole to the drinking water, D2 messenger RNA (mRNA) is increased 70% (P ϭ 0.03). Treatment with L-T 3 (50 g/100 g BW) for 4 days results in an 80% decrease in D2 mRNA compared with that in euthyroid controls (P Ͻ 0.001). Administration of lower doses of L-T 3 (0.25-3 g/100 g BW⅐day) is associated with a dose-dependent decrease in cortical D2 mRNA, but little or no change in D2 activity. The decrease in D2 mRNA in response to T 3 treatment can be demonstrated within 4 h. Treatment of hypothyroid rats for 2 weeks with graded doses of L-T 4 (0.1-1.5 g/100 g BW⅐day) results in a significant decrease in cortical D2 activity, but not mRNA. The association between D2 activity and D2 mRNA in euthyroid, hypothyroid, and hormone-treated rats across a full range of thyroidal states suggests that L-T 4 treatment is associated with greater changes in cortical D2 activity (via posttranslational effects) than mRNA, whereas L-T 3 treatment has a greater effect on decreasing D2 mRNA (i.e. pretranslational effects). In conclusion, these studies demonstrate both pre-and posttranslational regulation of cortical D2 expression. The relative contribution of each mechanism depends on the ambient thyroid hormone concentration. (Endocrinology 138: [5231][5232][5233][5234][5235][5236][5237] 1997) I N THE hypo-or hyperthyroid state, whole brain T 3 content is altered to a considerably lesser extent than observed in other organs, such as the liver (1, 2). This relative stability of brain T 3 level appears to be due at least in part to autoregulatory mechanisms within the brain itself that regulate both T 4 to T 3 conversion (3-5) and the metabolism of T 4 and T 3 to inactive compounds (6). For example, the fractional conversion of T 4 to T 3 in brain is increased in the hypothyroid state, whereas it is decreased by this condition in the liver (1, 2, 5, 7).
mRNA, but little or no change in D2 activity. The decrease in D2 mRNA in response to T 3 treatment can be demonstrated within 4 h. Treatment of hypothyroid rats for 2 weeks with graded doses of L-T 4 (0.1-1.5 g/100 g BW⅐day) results in a significant decrease in cortical D2 activity, but not mRNA. The association between D2 activity and D2 mRNA in euthyroid, hypothyroid, and hormone-treated rats across a full range of thyroidal states suggests that L-T 4 treatment is associated with greater changes in cortical D2 activity (via posttranslational effects) than mRNA, whereas L-T 3 treatment has a greater effect on decreasing D2 mRNA (i.e. pretranslational effects). In conclusion, these studies demonstrate both pre-and posttranslational regulation of cortical D2 expression. The relative contribution of each mechanism depends on the ambient thyroid hormone concentration. (Endocrinology 138: 5231-5237, 1997) I N THE hypo-or hyperthyroid state, whole brain T 3 content is altered to a considerably lesser extent than observed in other organs, such as the liver (1, 2) . This relative stability of brain T 3 level appears to be due at least in part to autoregulatory mechanisms within the brain itself that regulate both T 4 to T 3 conversion (3) (4) (5) and the metabolism of T 4 and T 3 to inactive compounds (6) . For example, the fractional conversion of T 4 to T 3 in brain is increased in the hypothyroid state, whereas it is decreased by this condition in the liver (1, 2, 5, 7) .
The type 2 iodothyronine 5Ј-deiodinase (D2) appears to be an important factor in the ability of the central nervous system to adapt to alterations in thyroid hormone status. This enzyme, which is present in the anterior pituitary gland and brown adipose tissue as well as in several regions of the brain (8 -10) , deiodinates T 4 at the 5Ј-position to form T 3 and appears to be the principal source of intracellular T 3 in these tissues (3-5, 7, 11) . D2 activity is rapidly and markedly altered by changes in thyroid hormone levels; hypothyroidism results in enhanced activity, whereas the opposite effect occurs in hyperthyroidism (9, 12, 13) . Furthermore, it has recently been reported that 90% of T 3 production in hypothyroid rats occurs in slowly exchanging tissues, such as brain and brown adipose tissue (BAT), where D2 predominates as the enzyme catalyzing T 4 to T 3 conversion (14) .
Several lines of evidence strongly suggest that posttranslational mechanisms are involved in the regulation of D2 activity by thyroid hormone (15) (16) (17) (18) (19) (20) (21) (22) . Specifically, thyroid hormones have been observed both in vivo in rodents and in several cell culture systems to induce a decrease in D2 activity that is more rapid than that observed when gene transcription or protein synthesis is blocked with actinomycin D or cycloheximide, respectively (15, 18, 19) . In addition, T 4 and rT 3 are considerably more potent that T 3 in inducing inactivation of D2 when administered acutely to hypothyroid animals (16, 18, 23, 24) . Given that transcriptional regulation by thyroid hormone is primarily, if not exclusively, mediated by T 3 binding to its nuclear receptors (25) , the greater potency of T 4 and rT 3 in acutely inhibiting D2 activity is further evidence that this process involves extranuclear metabolic events such as alterations in the rate of D2 protein turnover or translocation of the enzyme between various cellular compartments (19 -21, 26) .
In the present studies, we sought to determine whether the regulation of D2 in cerebral cortex might involve pretranslational as well as posttranslational mechanisms. A direct assessment of this possibility has only recently become feasible with the cloning of complementary DNAs (cDNAs) for this enzyme from several species (13, 27) . Indeed, initial studies in rats have demonstrated significant changes in D2 messenger RNA (mRNA) levels in BAT and the anterior pituitary gland in response to alterations in thyroid hormone status (13) . To assess the pretranslational regulation of D2 in the cerebral cortex by thyroid hormone, D2 mRNA and activity levels were compared in euthyroid and hypothyroid rats and in animals treated with graded doses of l-T 3 or l-T 4 .
Materials and Methods Materials
[␣-
32 P]deoxy-CTP, [ 125 I]rT 3 , and Gene Screen membranes were purchased from New England Nuclear (Boston, MA). Decaprime II oligolabeling kits were purchased from Ambion (Austin, TX). l-T 4 , l-T 3 , and methimazole (MMI) were purchased from Sigma Chemical Co. (St. Louis, MO). Reagents for determining protein concentration were obtained from Bio-Rad Laboratories (Richmond, CA).
Animals and treatments
All treatments were approved and in compliance with the requirements of the animal care and use committee of the University of Pittsburgh or Dartmouth Medical School. Male Sprague-Dawley rats, weighing 175-200 g, were purchased from Zivic Miller (Zelienople, PA), Harlan Sprague-Dawley (Indianapolis, IN), or Charles River Laboratories (Burlington, MA). Rats had free access to water and food at all times during the study. Hypothyroidism was induced by the addition of MMI (0.025% or 0.05%) to the drinking water. Hypothyroidism was assessed clinically by failure to gain weight at the expected rate and could be observed within 2 weeks of beginning MMI treatment.
In an initial study, the experimental groups (n ϭ 6 rats/group) included euthyroid control animals, animals receiving MMI for 4 weeks, and euthyroid animals treated with l-T 3 (50 g/100 g BW, sc, daily) for 4 days before death to induce a hyperthyroid state.
A second series of experiments was conducted using a longer period of thyroid hormone treatment. Rats taking MMI for 2 weeks were continued on this agent for an additional 2 weeks, during which time they were administered once daily ip injections of l-T 4 , l-T 3 , or 10 mm sodium hydroxide vehicle. Rats treated with l-T 4 received daily ip doses of 0.1 (n ϭ 6), 0.2 (n ϭ 6), 0.5 (n ϭ 6), 1.5 (n ϭ 10), 3 (n ϭ 5), 4.5 (n ϭ 5), or 10 g/100 g BW (n ϭ 4). Treatment with l-T 3 involved administering doses of 0.25 (n ϭ 10), 1 (n ϭ 6), 1.7 (n ϭ 4), 3 (n ϭ 4), or 5 (n ϭ 4) g/100 g BW. Sixteen rats receiving MMI, treated only with vehicle, served as hypothyroid controls. Six euthyroid rats served as additional controls. The chosen doses of administered thyroid hormone were based on previous reports suggesting that l-T 4 at 5-10 g/100 g BW⅐day induces thyrotoxicosis (28, 29) . Furthermore, T 3 nuclear receptor saturation with an accompanying alteration in the transcriptional activity of specific liver genes is induced with l-T 3 treatment in a dose of 15-50 g/day (30) or with a single dose of 200 g T 3 (31) . Serum T 4 , serum T 3 , T 3 uptake, and cortical D2 mRNA concentrations were measured at the time of death in all chronically treated animals. Hepatic type I iodothyronine deiodinase (D1) mRNA and activity and cerebral cortex D2 activity were assayed in selected samples, including euthyroid rats and those receiving MMI receiving vehicle or low dose l-T 3 or l-T 4 treatment (dosage range, 0.1-3 g/100 g BW).
The time course of thyroid hormone effects on D2 mRNA and activity was determined using rats rendered hypothyroid by the inclusion of MMI in their drinking water for 50 days. At the end of this period, animals were administered vehicle, 50 g l-T 4 (n ϭ 5), or 200 g l-T 3 (n ϭ 5) as a single ip dose 24 h before death. This experiment was repeated in MMI-treated rats who received vehicle or 200 g l-T 3 4, 12, or 24 h before death, and results were compared with those from a euthyroid control group (n ϭ 4/group). Serum T 4 , serum T 3 , T 3 uptake, and cortical D2 mRNA and activity were measured in all animals.
Rats were killed in the morning (24 h after the last dose of l-T 3 or l-T 4 , or as otherwise noted) under Nembutal anesthesia by exsanguination through the carotid arteries. Brains were quickly removed, and the cortex was dissected out on ice for storage at Ϫ80 C until RNA extraction or homogenization for activity.
Isolation and analysis of RNA
In the initial experiment, RNA was isolated, and Northern analysis was performed according to previously described procedures (13) using 20 g total RNA from the cerebral cortex of individual rats. Final wash conditions used 0.1 ϫ SSPE (sodium chloride, sodium phosphate, EDTA)-0.1% SDS at 60 C for 1 h. Quantitation of the hybridization signal was performed by phosphorimaging. The signal was corrected for differences in loading and transfer by reprobing the blot with a rat ␤-actin probe and determining the ratio of the D2 band to the ␤-actin band for each lane.
In other experiments, RNA extraction was performed by a modification of the guanidine thiocyanate method (32) and was quantitated by reading the optical density at 260 . Using 20 g total RNA/lane, agarose gel electrophoresis was performed under denaturing conditions (33) . The RNA was transferred overnight via capillary action to a nylon membrane and UV cross-linked (34) . An XbaI fragment of the rat D2 (13) or a PvuII fragment of the rat D1 cDNA (35) was labeled to high specific activity using the random primer technique and then hybridized to the membrane at 43 C for 24 -48 h (36, 37) . Membranes were washed at 63 C (for D2) or at 50 C (for D1) for a minimum of 40 min each in 2 ϫ SSC (standard saline citrate)-0.1% SDS, 25 mm NaHPO 4 (pH 7.2)-1 mm EDTA-0.1% SDS, and 25 mm NaHPO 4 (pH 7.2)-1 mm EDTA-1% SDS. Quantitation of mRNA density was performed by phosphorimaging the specific band with normalization to the 28S ribosomal RNA band to correct for variations in loading. The 28S band was visualized by ethidium bromide staining and photographed with type 665 positivenegative Polaroid film, and the density was quantitated by densitometry of the negative (38, 39) . The data are reported in relative units corrected for the amount of 28S RNA present in each lane. The relative level of D2 mRNA between gels and experiments was standardized to either a rat brain or liver standard placed on all gels.
Measurement of 5Ј-deiodinase activity
A portion of the cerebral cortex from individual animals was homogenized (1:5, wt/vol) in 0.25 m sucrose and 0.02 m Tris-HCl, pH 7.4, and assayed for D2 activity using 1 nm radiolabeled rT 3 as substrate and in the presence of 20 mm dithiothreitol, 1 mm EDTA, and 0.1 mm 6n-propyl-2-thiouracil, as previously described (13) . D2 activity is expressed as femtomoles/h⅐mg protein. Livers were homogenized at 1:10 in the same buffer, diluted 1:100, and assayed for D1 activity as described above, except that no 6n-propyl-2-thiouracil was included in the assay mixture. For a given experiment, all determinations were made in a single assay, with duplicate determinations for each sample. D1 activity is expressed as picomoles/h⅐mg protein. Protein concentrations were determined by the method of Bradford (40) .
Hormone measurements
Serum total T 4 , total T 3 , and T 3 uptake were measured by RIA (Coat-A-Count, Diagnostic Products Corp., Los Angeles, CA). A rat thyroid hormone binding ratio was obtained by normalizing the T 3 uptake determination to a rat euthyroid standard. Free T 4 index and free T 3 index were calculated by multiplying the serum total T 4 or total T 3 , respectively, by the thyroid hormone binding ratio. The T 4 and T 3 concentrations obtained in the study are expressed as micrograms per dl and nanogram per ml, respectively. The free T 4 index and free T 3 index are without units.
Statistical analysis
Statistical analysis was performed in some cases using log-transformed data. Where appropriate, linear regression was performed or comparisons between groups were assessed by ANOVA, with appropriate post-hoc mean comparisons by the method of Tukey (41) (Systat Program, Evanston, IL) or Dunnett's test for multiple comparisons with a control group. P Ͻ 0.05 is considered significant.
Results
Using a rat D2 cDNA probe, Northern analysis of total RNA from rat cerebral cortex identified a predominant and prominent band approximately 7 kilobases in length (Fig.  1a) . This is the same size RNA species identified previously on Northern blots of BAT, anterior pituitary, and cerebral cortex using polyadenylated RNA (13) . Quantitation of this 7-kilobase band by phosphorimager analysis permitted a comparison of the effects of hormone treatments on D2 mRNA levels. Representative blots of cerebral cortical RNA samples from hypothyroid rats and animals treated with l-T 3 and l-T 4 are shown in Fig. 1, b and c. In the initial experiment, D2 mRNA levels were compared in euthyroid rats, hypothyroid rats, and rats rendered hyperthyroid by the administration of high doses of l-T 3 (50 g/100 g BW⅐day) for 4 days. As shown in Fig. 2 , hypothyroidism was associated with a 70% increase in cortical D2 mRNA levels compared with those in euthyroid control animals (P ϭ 0.03). In contrast, T 3 administration for 4 days resulted in an 80% decrease in mRNA levels compared with levels in this control group (P Ͻ 0.001). Likewise, as shown in Table 1 , administration of T 3 (5 g/100 g BW⅐day) or T 4 (10 g/100 g BW⅐day) for 14 days to MMI-treated rats resulted in 59% and 71% decreases, respectively, in the cortical D2 mRNA level compared with that in the 28-day MMItreated hypothyroid group.
To examine the effects of physiological levels of thyroid hormone on the regulation of cortical D2 mRNA and activity, hypothyroid rats were treated for 2 weeks with daily doses of vehicle or l-T 3 ranging from 0.25-3 g/100 g BW. A group of euthyroid animals served as an additional control group. The administration of increasing doses of l-T 3 induced a significant increase in the serum free T 3 index (P Ͻ 0.001; Fig.  3a ). This was associated with a dose-dependent decrease in cerebral cortex D2 mRNA (P ϭ 0.006; Fig. 3b ). However, l-T 3 administration did not statistically alter the high levels of D2 activity observed in the hypothyroid state (P ϭ 0.31; Fig. 3c ). For comparison, hepatic D1 mRNA and activity were determined in the same animals (Fig. 3, d and e). As expected from prior studies (35, 42, 43) , D1 mRNA and activity progressively increased with increasing doses of T 3 (P Ͻ 0.001). Of note, significant increases in these parameters were noted at the lowest dose of T 3 administered (0.25 g/100 g BW⅐day), whereas higher doses (3 g/100 g BW⅐day) were required to effect inhibition of D2 mRNA in the cerebral cortex. T 3 treatment rapidly decreased cerebral cortical D2 mRNA levels. In an initial experiment, a single 200-g dose of l-T 3 was administered ip to hypothyroid rats 24 h before death. The D2 mRNA level decreased by 90% in the l-T 3 -treated animals (hypothyroid, 2.76 Ϯ 0.15; T 3 -treated, 0.27 Ϯ 0.18; P ϭ 0.003; n ϭ 5/group). In a second experiment, D2 mRNA and activity levels were determined 4, 12, and 24 h after l-T 3 administration. As shown in Fig. 4a , the free T 3 index was increased markedly by 4 h after l-T 3 administration and remained elevated for 24 h (P Ͻ 0.001). Associated with this, the D2 mRNA level was significantly decreased at 4 h (P Ͻ 0.01; Fig. 4b ) and declined further at 12-24 h (P Ͻ 0.001). This was associated with a progressive decrease in D2 activity (P ϭ 0.02; Fig. 4c ) that appeared to be somewhat delayed and of lesser magnitude than the changes in the D2 mRNA level. The effects of chronic l-T 4 treatment on cortical D2 and hepatic D1 mRNA and activity were also examined. As in the l-T 3 experiment, hypothyroid rats were administered vehicle or l-T 4 daily in doses ranging from 0.1-1.5 g/100 g BW⅐day for 2 weeks. Animals were killed 24 h after the last dose. Significant increases in free T 4 index and free T 3 index were observed in a dose-dependent fashion, with the largest dose administered resulting in values at 24 h comparable to those observed in the euthyroid control group (P Ͻ 0.001; Fig. 5,  a and b) . Although cerebral cortical D2 activity significantly decreased (P Ͻ 0.001), cortical D2 mRNA remained relatively stable, with the exception of an apparent increase in mRNA associated with the 0.1 g/100 g BW⅐day l-T 4 dose that proved not to be statistically significant (P ϭ 0.13 vs. hypothyroid rats). Again, as expected, hepatic D1 mRNA and activity could be readily induced by l-T 4 treatment (P Ͻ 0.001, Fig. 5, a and c) .
The relationship between cortical D2 mRNA and activity in euthyroid, hypothyroid, and l-T 4 -and l-T 3 -treated rats is illustrated in Fig. 6 . These data represent the values for the individual animals from the experiments depicted in Figs. 3 and 5 as well as other confirmatory experiments not shown. Here, it can be seen that the transition from the euthyroid to the hypothyroid state is associated with a relatively larger increase in D2 activity than in mRNA concentration. When comparing the effects of T 4 vs. T 3 treatment on these parameters, it is apparent that T 4 treatment is associated with large changes in D2 activity relative to alterations in mRNA levels, whereas the opposite occurs with T 3 treatment, in that mRNA levels are primarily affected.
The relationships between serum T 3 levels and cortical D2 mRNA and activity are shown in Fig. 7 . A highly significant inverse linear relationship is observed between log D2 mRNA and the log serum free T 3 index ( Fig. 7a ; r ϭ 0.520 and P Ͻ 0.001; r ϭ 0.61 if we exclude the outlier), with overlap in the values regardless of whether the animals were treated with l-T 4 or l-T 3 . No such relationship was found between log D2 mRNA and log serum free T 4 index (r ϭ 0.115; P ϭ 0.213). In contrast to Fig. 7a, a marked difference was noted   FIG. 3 . Effects of L-T 3 administration on cortical and hepatic deiodinase expression. Hypothyroidism was induced with MMI treatment for 28 days. Animals were administered L-T 3 (0.25-3 g/100 g BW⅐day) or vehicle by ip injection once daily during the last 2 weeks of treatment. They were killed in the morning, 24 h after the last dose of L-T 3 . Six euthyroid rats served as a separate control group. a, Free T 3 index; b, cerebral cortex D2 mRNA; c, cerebral cortex D2 activity; d, hepatic D1 mRNA; e, hepatic D1 activity. *, P Ͻ 0.001; †, P Ͻ 0.05 (relative to zero dose hypothyroid vehicle in post-hoc analysis). Values are the mean Ϯ SEM (n ϭ 6/group). in T 4 -and T 3 -injected animals in the relationship between the log D2 activity and the log free T 3 index ( Fig. 7b ; T 4 -treatment: r ϭ 0.74; P Ͻ 0.001; T 3 treatment: r ϭ 0.65; P Ͻ 0.001). Thus, for any given level of free T 3 index, D2 activity was significantly lower in the T 4 -treated animals than in those given T 3 . Of importance, the euthyroid control group (indicated by the box in Fig. 7b ) falls along the line for the T 4 -injected animals, suggesting that T 4 exerts the dominant controlling effect on D2 activity in the euthyroid animal.
Discussion
Previous studies using both in vivo and in vitro model systems have clearly demonstrated the importance of posttranslational mechanisms in the regulation of D2 activity by thyroid hormones (15) (16) (17) (18) (19) (20) (21) (22) . Significant effects of thyroid status on D2 mRNA levels in the anterior pituitary gland and BAT have also recently been reported (13) . The present studies extend these observations by demonstrating that pretranslational regulation of D2 also occurs in the rat cerebral cortex in response to altered thyroid status. Thus, hypothyroidism resulted in a significant increase in D2 mRNA levels compared with those in euthyroid control animals, whereas the administration of either T 3 or T 4 rapidly decreased transcript levels. These changes in thyroid status were associated with alterations in D2 mRNA levels over an approximately 10-fold range of values.
In confirmation of previous studies (16, 44) , treatment of hypothyroid rats with l-T 4 resulted in a greater degree of inhibition of D2 activity than did administration of similar doses of l-T 3 . In addition, l-T 4 administration resulted in greater proportional changes in D2 activity relative to alterations in mRNA levels. For example, chronic l-T 4 administered to hypothyroid animals at a dose of 0.2 g/100 g BW⅐day resulted in a significant inhibition of D2 activity, yet no change in D2 mRNA levels occurred. Indeed, treatment with l-T 4 at doses as high as 1.5 g/100 g BW⅐day did not significantly decrease cortical D2 mRNA, whereas it had a profound effect on inhibiting D2 activity. Such observations are compatible with a predominantly posttranslational mechanism of D2 inhibition by l-T 4 . In contrast, treatment with l-T 3 resulted in larger changes in D2 mRNA levels than in activity. Thus, l-T 3 treatment at 3 g/100 g BW⅐day did not significantly decrease cortical activity, but it was associated with a significant decrease in cortical D2 mRNA, suggesting a primary effect of this thyroid hormone on pretranslational D2 regulation. However, at high doses of administered hormone [chronic l-T 3 (5 g/100 g BW⅐day), l-T 4 (10 g/100 g BW⅐day), or l-T 3 (200 g), or l-T 4 (50 g) as a single ip dose 24 h before death], the level of cerebral cortex D2 mRNA suppression was the same with either l-T 4 or l-T 3 (data not shown).
The predominant effect of thyroidal status on regulating D2 activity occurs in the transition from the euthyroid to the hypothyroid state, whereas D2 mRNA levels appear to vary across the entire range of thyroid hormone levels. Thus, the relative importance of the pretranslational and posttransla- Six euthyroid rats served as a separate control group. a, Free T 4 index and free T 3 index; b, cerebral cortex D2 mRNA and activity; c, hepatic D1 mRNA and activity. *, P Ͻ 0.001; †, P Ͻ 0.05; ¥, P ϭ 0.053 (compared with hypothyroid vehicle-treated rats). Values are the mean Ϯ SEM (n ϭ 6/group).
FIG. 6. Log D2 activity vs. log relative D2 mRNA concentration. The data are taken from 85 rats used in the previously described experiments. ϩ, T 4 -treated hypothyroid rats (n ϭ 28; dose range, 0.1-20 g/100 g BW⅐day); f, L-T 3 -treated hypothyroid rats (n ϭ 27; dose range, 0.25-80 g/100 g BW⅐day); E, vehicle-treated hypothyroid rats (n ϭ 20). Ⅺ, Mean of a group of euthyroid rats (n ϭ 10). Linear regression was performed on the L-T 3 plus vehicle group (r ϭ 0.64; P Ͻ 0.001) or on the L-T 4 plus vehicle group (r ϭ 0.56; P Ͻ 0.001).
tional mechanisms in regulating D2 expression probably depends on the intracellular concentrations of both l-T 3 and l-T 4 . These dual mechanisms of regulating D2 expression may work in concert to ensure that D2 activity, and thus T 4 to T 3 conversion, is appropriate to maintain the cortex in a euthyroid state. Of note, the posttranslational effects of l-T 4 on D2 activity have been demonstrated to occur rapidly (in Ͻ2 h) (12, 15) , whereas the effects of l-T 3 in inhibiting D2 mRNA appear to take somewhat longer. Thus, the pretranslational mechanism of D2 regulation may assume greater importance over a more chronic time frame. It is also interesting to speculate that a decrease in D2 mRNA in the hyperthyroid state may, by decreasing translation of the D2 protein, allow for the conservation of selenocysteine so that it can be directed into the synthesis of other essential selenoproteins, such as D3, whose activity is increased in this condition.
Differences were noted in these studies in the apparent sensitivity of cortical D2 and hepatic D1 to regulation by thyroid hormones. For example, low doses of l-T 3 that did not affect cortical D2 activity or mRNA levels did induce significant increases in hepatic D1 mRNA and activity. This finding may reflect the observations of others that tissue concentrations of T 3 are higher in the liver than in the cerebral cortex over a range of thyroid states (45, 46) . Alternatively, these differences may indicate an inherently greater sensitivity of hepatic D1, compared with cortical D2, to pretranslational regulation by l-T 3 . In contrast, the exquisite sensitivity of D2 in the brain to posttranslational regulation by l-T 4 is evident by the marked inhibition of D2 activity by administered doses of this hormone that have little or no effect on hepatic D1 levels.
In conclusion, we have demonstrated that D2 in the rat cerebral cortex is regulated by thyroid hormones at a pretranslational as well as a posttranslational level. This provides an additional mechanism of autoregulatory control over the activity of this important enzyme.
